Literature DB >> 3523393

Iontophoresis of vincristine versus saline in post-herpetic neuralgia. A controlled trial.

Paul R Layman1, Eri Argyras, Christopher J Glynn.   

Abstract

Twenty patients with post-herpetic neuralgia (median duration 28.5 months) were randomly allocated to receive transdermal iontophoresis of either vincristine or saline. Although significant improvement in pain by word score and visual analogue scale (P = 0.05) was reported by 6 out of 10 of the vincristine group, none of the patients considered themselves 'cured.' There was no significant change in the saline group. No adverse haematological or neurological side effects were seen, but skin irritation and painless electrical burns were common in both groups. The dramatic relief of pain in patients with post-herpetic neuralgia of 3 months or less reported elsewhere was not seen in our group who had pain of a longer duration. This present trial does not confirm the value of vincristine iontophoresis in the treatment of post-herpetic neuralgia of over 6 months duration.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3523393     DOI: 10.1016/0304-3959(86)90090-4

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  4 in total

Review 1.  Herpes zoster management.

Authors:  J A Katz; J C Phero; J S McDonald; D B Green
Journal:  Anesth Prog       Date:  1989 Mar-Apr

2.  Iontophoresis using a local anesthetic for the treatment of pediatric acute herpetic pain.

Authors:  Kenji Kodama; Yoshiro Sakaguchi; Takato Morioka; Chiaki Miyazaki; Masamune Tominaga; Etsuko Kanna; Shosuke Takahashi
Journal:  J Anesth       Date:  1998-06       Impact factor: 2.078

3.  [Pain therapy in herpes zoster and post-zoster neuralgia.].

Authors:  T Zenz; M Zenz; M Tryba
Journal:  Schmerz       Date:  1994-03       Impact factor: 1.107

Review 4.  Analgesic therapy in postherpetic neuralgia: a quantitative systematic review.

Authors:  Kathleen Hempenstall; Turo J Nurmikko; Robert W Johnson; Roger P A'Hern; Andrew S C Rice
Journal:  PLoS Med       Date:  2005-07-26       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.